Article Contents ::
- 1 Details About Generic Salt :: Thiorida
- 2 Main Medicine Class:: Antipsychotic,phenothiazine; antiemetic
- 3 (THIGH-oh-RID-uh-zeen HIGH-droe-KLOR-ide) Mellaril, Mellaril-S, Thioridazine HCl Intensol, Apo-Thioridazine, Novo-Ridazine, PMS-Thioridazine Class: Antipsychotic/phenothiazine; antiemetic
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Thiorida
Main Medicine Class:: Antipsychotic,phenothiazine; antiemetic
Mellaril, Mellaril-S, Thioridazine HCl Intensol, Apo-Thioridazine, Novo-Ridazine, PMS-Thioridazine
Class: Antipsychotic/phenothiazine; antiemetic
Drugs Class ::
Action Effects apparently due to dopamine receptor blocking in CNS.
Indications for Drugs ::
Indications Management of psychotic disorders (eg, schizophrenia); short-term treatment of moderate to marked depression with variable degrees of anxiety in adults; reatment of multiple symptoms (eg, agitation, anxiety, depressed mood, tension, sleep disturbances and fears) in geriatric patients; treatment of severe behavioral problems in children marked by combativeness or explosive hyper-excitable behavior; short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders. Treatment of Tourette’s syndrome, acute agitation in elderly and some symptoms of dementia.
Drug Dose ::
ADULTS: PO 200–800 mg/day in divided doses. For moderate disorders, start with 10 mg bid-tid. Do not exceed 800 mg/day. CHILDREN 13–18 YR: PO 25–800 mg/day. CHILDREN 7–12 YR: PO 25–500 mg/day. CHILDREN 3–6 YR: PO 10–100 mg/day. CHILDREN 2–12 YR: PO Usually 0.5–3 mg/kg/day. HOSPITALIZED, SEVERELY DISTURBED, OR PSYCHOTIC CHILDREN: PO 25 mg bid-tid. ELDERLY: PO 20–200 mg/day.
Contraindications Comatose or severely depressed states; allergy to this or any phenothiazine; resence of large amounts of other CNS depressants; bone marrow depression or blood dyscrasias; liver damage; extensive cerebral arteriosclerosis; severe coronary artery disease; severe hypotension or hypertension; subcortical brain damage.
Drug Precautions ::
Pregnancy: Safety not established. Lactation: Safety not established. Children: Not recommended in children < 2 yr. Elderly patients: More susceptible to effects; consider lower dose. Special risk patients: Use caution in patients with cardiovascular disease or mitral insufficiency, history of glaucoma, EEG abnormalities or seizure disorders, prior brain damage, hepatic or renal impairment. CNS effects: May impair mental or physical abilities, especially during first few days of therapy. Hepatic effects: Jaundice usually occurs between 2nd and 4th weeks of treatment; considered hypersensitivity reaction. Usually reversible. Neuroleptic malignant syndrome (NMS): Has occurred with agents of this class; is potentially fatal. Signs and symptoms are hyperpyrexia, muscle rigidity, altered mental status, irregular pulse, irregular blood pressure, tachycardia and diaphoresis. Pulmonary: Cases of bronchopneumonia, some fatal, have occurred. Sudden death: Has been reported; predisposing factors may be seizures or previous brain damage. Flareups of psychotic behavior may precede death.
PATIENT CARE CONSIDERATIONS
Drug Side Effects ::
CV: Orthostatic hypotension; hypertension; tachycardia; bradycardia; yncope; cardiac arrest; circulatory collapse; lightheadedness; faintness; izziness; Ekg changes. CNS: Pseudoparkinsonism; dystonias; motor restlessness; headache; weakness; remor; fatigue; slurring; insomnia; vertigo; seizures; tardive dyskinesia; rowsiness; paradoxical excitement; headache; confusion. DERM: Photosensitivity; skin pigmentation; dry skin; exfoliative dermatitis; rticarial rash; maculopapular hypersensitivity reaction; seborrhea; eczema. EENT: Pigmentary retinopathy; glaucoma; photophobia; blurred vision; mydriasis; ncreased IOP; dry throat; nasal congestion. GI: Dyspepsia; constipation; dry mouth; adynamic ileus. GU: Urinary hesitancy or retention; impotence; sexual dysfunction; dysmenorrhea; enstrual irregularities. HEMA: Agranulocytosis; eosinophilia; leukopenia; hemolytic anemia; hrombocytopenic purpura. HEPA: Jaundice. META: Decreased cholesterol. RESP: Laryngospasm; respiratory depression; bronchospasm; dyspnea. OTHER: Increase in appetite and weight; polydipsia; breast enlargement; galactorrhea; euroleptic malignant syndrome.
Drug Mode of Action ::
Action Effects apparently due to dopamine receptor blocking in CNS.
Drug Interactions ::
Alcohol and other CNS depressants: May result in increased CNS depression and may precipitate extrapyramidal reaction. Anticholinergics: May reduce therapeutic effects of thioridazine and worsen anticholinergic effects of thioridazine. May lead to tardive dyskinesia. Barbiturate anesthetics: Frequency and severity of neuromuscular excitation and hypotension may increase. Beta-blockers: May result in increased plasma levels of beta-blocker and thioridazine. Epinephrine: May antagonize effects of epinephrine. Lithium: May cause disorientation, unconsciousness and extrapyramidal effects.
Drug Assesment ::
- Obtain patient history, including drug history and any known allergies.
- Assess mental status before initial administration.
- Check to ensure patient has swallowed drug.
- Monitor vital signs and check orthostatic BP and pulse before treatment and q 4 hr during therapy.
- Assess for signs of liver dysfunction (jaundice, light-colored stools, palpable liver).
- Monitor bilirubin, CBC and LFTs monthly.
- Assess alcohol consumption.
- Monitor for signs of tardive dyskinesia and other extrapyramidal symptoms and assess need for antiparkinson agent.
- Assess ECG for rhythm disturbances.
- Notify physician of changes in vital signs, ECG, or cardiac status.
- Notify physician if patient demonstrates psychiatric changes.
- Monitor I&O. Palpate bladder if urine output is decreased.
- Supervise ambulation until patient is stable.
- Increase fluid intake to prevent constipation.
- Provide sips of water, sugarless candy or sugarless gum to relieve dry mouth.
Drug Storage/Management ::
- If using concentrate, do not mix with beverages containing caffeine, tannins or apple juice. Examples of possible mixing solutions include milk, saline, pineapple, orange-flavored soda, tomato juice, apricot or grapefruit juice.
- Avoid contact with skin.
- Store in tight, light-resistant container.
Drug Notes ::
- Caution patient not to consume alcohol and to avoid otc medications while taking drug.
- Explain changes in urine color that may occur with this medication.
- Tell patient to report flank pain or changes in urination other than expected color changes.
- Tell patient to report signs of liver dysfunction, such as light-colored stools or jaundice.
- Explain type and potential significance of tardive dyskinesia such as changes in control of facial muscles.
- Instruct patient to avoid sudden position changes to prevent orthostatic hypotension.
- Caution patient to avoid hot tubs and hot showers and baths since hypotension may occur.
- Tell patient/family to report seizures, headaches, faint feeling, dizziness, or changes in mental function.
- Tell patient to use precautions against photosensitivity reactions. Advise use of sunscreen.
- Stress good oral hygiene.
- Caution patient not to drive while on medication, as may cause drowsiness or dizziness.
- Inform patient that in hot weather patient may have increased risk of heat stroke and increased sensitivity to sun.